RZLT
Rezolute, Inc.
NASDAQ · Healthcare · Biotechnology · US
$4.58
+0.88%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | — | — | — | — | — |
| Cost of Revenue | 23.0K | — | — | — | — |
| Gross Profit | (23.0K) | — | — | — | — |
| Operating Expenses | |||||
| R&D Expense | 59.8M | 61.5M | 55.7M | 43.8M | 32.5M |
| SG&A Expense | 27.6M | 18.4M | 14.7M | 12.2M | 9.4M |
| General & Admin Expense | 27.4M | 18.4M | 14.7M | 12.2M | 9.4M |
| Selling & Marketing Expense | 167.0K | — | — | — | — |
| Other Expenses | (120.0K) | — | — | — | — |
| Total Operating Expenses | 87.2M | 79.9M | 70.4M | 56.0M | 41.8M |
| Cost and Expenses | 87.3M | 79.9M | 70.4M | 56.0M | 41.8M |
| Operating Income (EBIT) | (87.3M) | (79.9M) | (70.4M) | (56.0M) | (41.8M) |
| Non-Operating | |||||
| Interest Income | 5.8M | 5.5M | 4.9M | 4.2M | 80.0K |
| Interest Expense | — | — | — | — | 1.8M |
| Net Interest Income | 5.8M | 5.5M | 4.9M | 4.2M | (1.7M) |
| Other Non-Op Income/Expense | 5.8M | 5.5M | 2.0M | 4.2M | 783.0K |
| Non-Operating Income (excl Interest) | (5.8M) | (5.5M) | (2.0M) | (4.2M) | (2.6M) |
| EBT (Pre-Tax Income) | (81.5M) | (74.4M) | (68.5M) | (51.8M) | (41.1M) |
| Income Tax Expense | — | — | — | — | — |
| Bottom Line | |||||
| Net Income | (81.5M) | (74.4M) | (68.5M) | (51.8M) | (41.1M) |
| Earnings from Cont. Ops | (81.5M) | (74.4M) | (68.5M) | (51.8M) | (41.1M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (81.5M) | (74.4M) | (68.5M) | (51.8M) | (45.1M) |
| Per Share | |||||
| Basic EPS | ($0.82) | ($0.98) | ($1.33) | ($1.01) | ($2.26) |
| Diluted EPS | ($0.82) | ($0.98) | ($1.33) | ($1.01) | ($2.32) |
| Revenue Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 104.0M | 76.0M | 51.5M | 51.2M | 18.2M |
| Diluted Shares Outstanding | 104.0M | 76.0M | 51.5M | 51.2M | 19.5M |
| Profitability Metrics | |||||
| EBITDA | (81.5M) | (74.4M) | (68.4M) | (51.8M) | (39.2M) |
| D&A | 31.0K | 31.0K | 36.0K | 30.0K | 13.0K |
| EBIT | (81.5M) | (74.4M) | (68.5M) | (51.8M) | (39.3M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026